• OTS
  • April 30, 2019
SHARE
Post Views: 858

Nimjee SM, Dornbos D 3rd, Pitoc GA, Wheeler DG, Layzer JM, Venetos N, Huttinger A, Talentino SE, Musgrave NJ, Moody H, Rempel RE, Jones C, Carlisle K, Wilson J, Bratton C, Joseph ME, Khan S, Hoffman MR, Sommerville L, Becker RC, Zweier JL, Sullenger BA.
Mol Ther. 2019 Mar 30. pii: S1525-0016(19)30110-8.

PubMed

Related articles

How to Develop and Prove High-Efficiency Selection of Ligands from Oligonucleotide Libraries: A Universal Framework for Aptamers and DNA-Encoded Small-Molecule Ligands

How to Develop and Prove High-Efficiency Selection of Ligands from Oligonucleotide Libraries: A Universal Framework for Aptamers and DNA-Encoded Small-Molecule Ligands

April 23rd, 2021
Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

April 23rd, 2021
Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation

Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation

April 23rd, 2021
Hovlinc is a recently evolved class of ribozyme found in human lncRNA

Hovlinc is a recently evolved class of ribozyme found in human lncRNA

April 23rd, 2021
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

April 23rd, 2021
Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

March 15th, 2021